Biotechnologia Acta

...

  • Increase font size
  • Default font size
  • Decrease font size
Home Archive 2020 № 6 "QUALITY BY DESIGN" IN LIPOSOMAL DRUGS CREATION Yu. М. Krasnopolsky, D. М. Pylypenko
Print PDF

ISSN 2410-7751 (Print)
ISSN 2410-776X (Online)

Biotechnologia Acta V. 13, No 6, 2020
Р. 5-12, Bibliography 64, English
Universal Decimal Classification: 615.014:615.456.3
https://doi.org/10.15407/biotech13.06.005

"QUALITY BY DESIGN" IN LIPOSOMAL DRUGS CREATION

Yu. М. Krasnopolsky, D. М. Pylypenko

National Technical University "Kharkiv Polytechnic Institute", Ukraine

Nanobiotechnological preparations creation is one of the promising areas of modern pharmacy, since it allows creating products of a qualitatively new level. The procedure development, based on an understanding of the product characteristics and the technological process, confirmed by reliable scientific data.

The article is devoted to the pharmaceutical development of liposomal drugs. On the basis of our own experience in the development of liposomal medicinal forms, as well as on the basis of literature data, the main components in their composition were detected and these components impact on the quality indicators of liposomes were studied. Individual lipids function in nanoparticle membrane and their interaction, which determines the stability both in the technological process and upon storage of the product, were considered. The advantages and disadvantages of cholesterol incorporation into liposomes with hydrophilic and hydrophobic active pharmaceutical ingredients were described. Cryoprotectors and buffer systems role in ensuring nanopreparation stability is discussed.

Key words:. liposomes, phospholipids, cholesterol, cryoprotector, buffer system, Quality by Design.

© Palladin Institute of Biochemistry of National Academy of Sciences of Ukraine, 2020

  • References
    • 1. Ranghar S., Sirohi P., Verma P., Agawal V. Nanoparticle-based drug delivery system. Braz. arch. biol. technol. 2014, 57 (2), 209–222. https://doi.org/10.1590/S1516-89132013005000011

      2. Akbani J., Bashiz M. Nanomedicine and its role in Ophthalmology. J. Cont. Med. 2014, 2 (3), 1‒10. http://dx.doi.org/10.18049/jcmad/231

      3. Khromov A. S. Liposomal drugs – implementation of nanotechnology in medicine. Farmakolohiia ta likarska toksykolohiia. 2016, 2 (48), 14‒23. (In Russian).

      4. Shvets V. I., Krasnopolskiy Yu. M., Sorokoumova G. M. Liposomal forms of drugs: technological features of production and use in the clinic. Moskva: Remedium. 2016, 200 p. (In Russian).

      5. Krasnopolskii Y. M., Grigoreva A. S., Katsai A. G., Konakhovich N. F., Prokhorov V. V., Stadnichenko A. V., Balabanyan V. Yu., Lyutik A. I., Shvets V. I. Technologies and perspectives of liposomal drug application in clinical practice. Nanotechnol. Russ. 2017, 12 (7‒8), 461–470. http://doi.org/10.1134/s1995078017040139

      6. Bulbake U., Doppalapudi S., Kommineni N., Khan W. Liposomal formulations in clinical use: an updated review. Pharmaceutics. 2017, 9 (2), 12. https://doi.org/10.3390/pharmaceutics9020012

      7. Allen T. M., Cullis P. R. Liposomal drug delivery systems: from concept to clinical application. Adv. Drug. Deliv. Rev. 2013, 65 (1), 36–48. https://doi.org/10.1016/j.addr.2012.09.037

      8. Golombek S. K., May J. N., Theek B., Appold L., Drude N., Kiessling F., Lammers T. Tumor Targeting via EPR: Strategies to Enhance Patient Responses. Adv. Drug Deliv. Rev. 2018, V. 130, P. 17–38. https://doi.org/10.1016/j.addr.2018.07.007

      9. Pawar H. R., Bhosale S. S., Derle N. D. Use of liposomes in cancer therapy: a review. Int. J. Pharm. Sci. Res. 2012, 3 (10), 3585‒3590. http://dx.doi.org/10.13040/IJPSR.0975-8232.3(10).3585-90

      10. Stefanov O. V., Temirov Yu. P., Krasnopolskyi Yu. M. А method of obtaining a liposomal drug. Ukrainian patent No. 5654. December 28, 1994.

      11. Hryhorieva A. S., Konakhovych N. F., Stefanov O. V., Krasnopolskyi Yu. M., Temirov Yu. P., Riabushev M. B. А method of obtaining a liposomal hepatoprotective agent. Ukrainian patent No. 46528. December 15, 2003.

      12. Dudnychenko A. S., Temirov Yu. P., Shvets V. I., Krasnopolskyi Yu. M., Sennikova I. H. A method of obtaining a liposomal form of an antitumor antibiotic. Ukrainian patent No. 64591. January 16, 2006.

      13. Stefanov O. V., Hryhorieva H. S., Solovev O. I., Psechnikova N. V., Khromov O. S., Konakhovych N. F., Krasnopolskyi Yu. M. А method of obtaining a liposomal agent containing quercetin. Ukrainian patent No. 76393. July 17, 2006.

      14. Grygor'ieva G. S., Krasnopol'skyy I. M., Konajovych N. P., Pasechnikova N. V. Method of obtaining active liposomal quercetin-containing product. Patent WO/2016/007114. January 14, 2016.

      15. Iukhymets V. O. Prospects for the use of the drug Lipin in pulmonology. Liky. 1995, N 4, P. 19–28. (In Ukrainian).

      16. Keshichyan E. S., Krasnopolskiy Yu. M., Titova L. G., Nisan L. G. The use of Lipin for the correction of gas exchange in the lungs in newborns who underwent prolonged artificial ventilation of the lungs. 2-y Rossiiskii Natsionalnyi kongress «Chelovek i lekarstvo», Moskva. 1995, P. 162‒163. (In Russian).

      17. Novikova R. I., Chernyj V. I., Stefanov A. V., Ahlamova Ju. M. Liposomes in the complex treatment of patients with chronic obstructive bronchitis. Terapevticheskii arkhiv. 1993, N 3, P. 40–43. (In Russian).

      18. Akimova I. K., Hovorukha I. H., Stefanov O. V., Yakubenko O. D. Lipin in the complex treatment of pregnant women with late preeclampsia. Liky. 1995, N 5, P. 39‒43. (In Ukrainian).

      19. Limarev V. А. Clinical efficacy of use of phosphatidylcholine liposom (lipine) in treatment of PCOD with anemic syndrome in patients, who had pulmonary tuberculosis. Krymskii terapevticheskii zh. 2011, N 1, P. 79–82. (In Russian).

      20. Pertseva T. O., Kyreeva T. V., Shtepa O. O. Possibilities of correction of the surfactant system of the lungs in patients with lower respiratory tract infections. Methods of efficiency control. Visnyk naukovykh doslidzhen. 2015, N 3, P. 34–38. (In Ukrainian).

      21. Ignatenko G. A., Mukhin I. V., Uzun D. Y. Liposomal therapy of postimplantation atrial fibrillation in age patients category with dual chamber pacemakers. Fundamentalnye issledovaniya. 2015, 1 (1), 83–86. (In Russian).

      22. Krasnopol'skij Ju. M., Dranov A. L., Stepanov A. E., Shvec V. I. Liposomal forms of cytostatics in oncology. Vestnik Rossiiskoi Akademii Meditsinskikh nauk. 1998, N 5, P. 35–40. (In Russian).

      23. Kulik G. I., Ponomareva O. V., Korol V. I., Chehun V. F. Toxicity and anti-inflammatory activity of the liposomal dosage form of doxorubicin. Oncol. 2004, N 6, P. 207–214. (In Russian).

      24. Pivnuk V. M., Tymovska Yu. O., Ponomareva O. V., Kulyk G. I., Olyinichenko G. P., Anikusko M. F., Krasnopolsky Yu. M., Chekhun V. F. Applying of liposomal form of doxorubicin in patients with doxorubicin-resistant breast cancer. Oncol. 2007, 9 (2), 120–124. (In Ukrainian).

      25. Bіletskyi V. E., Dudnichenko O. S. The long-term results of using free and liposomal doxorubicin in children with solid tumours. Problemy bezperervnoi medychnoi osvity ta nauky. 2017, N 1, P. 44‒48. (In Russian). https://doi.org/10.31071/promedosvity2017.01.044

      26. Drogovoz S. M., Shhekina E. G., Ushakova A. Modern approaches to the therapy of diseases of the hepatobiliary system. Provizor. 2008, N 8, P. 27–34. (In Russian).

      27. Kharchenko V. V. Modern approaches to pathogenetic treatment of patients with alcoholic liver disease. Ph.D. thesisi. Lugansk State Medical University of Health Protection Ministry of Ukraine, Lugansk. 2003. (In Ukrainian).

      28. Pasechnikova N. V., Gorshkova R. A. Clinical and biochemical rationale for the use of the drug "Lipoflavon" in patients with age-related cataracts after cataract extraction and implantation of peroxidation products. Ukrainskyi medychnyi almanakh. 2006, 9 (1), 219–221. (In Russian).

      29. Ivanova N. V., Jarosheva N. A. Pathogenetic rationale for the use of Lipoflavone in patients with various forms of diabetic retinopathy. Klinicheskaia farmakologiya. 2008, 12 (2), 11–16. (In Russian).

      30. Muhin I. V., Rodin I. N. Membranoprotective properties of liposomal preparations in comorbid renopulmonary pathology. Pytannia eksperymentalnoi ta klinichnoi medytsyny. 2009, 2 (13), 63–67. (In Russian).

      31. Tret'jakova O. S., Zadniprjanskij I. V. Cardioprotective capabilities of liposomes in the treatment of hypoxic damaged myocardium of newborns. Perinatologiya i pediatriya. 2011, 46 (2), 122–126. (In Russian).

      32. Shobolov D. L., Krasnopol'skij Ju. M., Ul'janov A. M., Natykan A. A., Tarasov V. V., Balaban'jan V. Ju., Shvec V. I. Method of obtaining liposomal form of irinotecan. Eurasian patent No. 023079. April 29, 2016.

      33. Stadnichenko A. V., Dudnichenko A. S., Krasnopolskiy Yu. M. Liposomal anticancer drugs. Kharkiv: «Madrid». 2018, 256 p. (In Russian).

      34. Stadnichenko A. V., Krasnopolsky Yu. M., Yarnykh T. G., Kotvitskaya A. A., Buryak M. V. The Concept “Quality by Design” in development of liposomal cytostatics. Res. J. Pharm. Tech. 2020, 13 (2), 674–678. https://doi.org/10.5958/0974-360X.2020.00129.8

      35. Hryhorieva H. S., Katsai O. H., Krasnopolskyi Yu. M., Prokhorov V. V., Khromov O. S., Pasiechnikova N. V., Dobrelia N. V. The method of obtaining a pharmacologically active liposomal composition containing cytochrome C, and a liposomal composition obtained by this method. Ukrainian patent No. 118583. February 11, 2019.

      36. Katsai O. G., Ruban O. A., Krasnopolskyi Y. M. Preparation and in vivo evaluation of cytochrome C-containing liposomes. Pharmazie. 2017, 72 (12), 736–740.

      37. Katsai O., Ruban O., Krasnopolskyi Y. “Quality-by-De­sign” approach to the development of a dosage form the liposomal delivery system of cytochrome C. Pharmatseftika. 2018, 30 (1), 76–87.

      38. Shakhmaev A. E., Horbach T. V., Krasnopolskyi Yu. M. The method of obtaining a cardioprotective agent based on liposomal nanoparticles. Ukrainian patent № 91702. July 10, 2014.

      39. Shakhmaiev A. E., Gorbach T. V., Bobritskaya L. A., Krasnopolsky Yu. M. Preparation and cardioprotective effect analysis of liposomal coenzyme Q10. The Pharma Innovation J. 2015, 4 (9), 22–26.

      40. Pylypenko D. M., Gorbach T. V., Katsai O. G., Grigoryeva A. S., Krasnopolsky Y. M. A Study of Oxidative Stress Markers when Using the Liposomal Antioxidant Complex. Pharmakeftiki. 2019, 31 (1), 40–47.

      41. Pylypenko D., Krasnopolsky Y. Extraction and purification of curcuminoids from Curcuma longa L. rhizome. Ukrainskyi biofarmatsevtychnyi zh. 2019, 4 (61), 60–64. (In Ukrainian). https://doi.org/10.24959/ubphj.19.238

      42. Dudnychenko O. S., Temirov Yu. P., Shvets V. I., Krasnopolskyi Yu. M., Sennikova I. H. А method of obtaining the liposomal form of the antitumor drug platinum. Ukrainian patent No. 66633. February 15, 2006.

      43. Kulik G. I., Pivnyuk V. M., Nosko M. M., Todor I. N., Chekhun V. F. Liposomal drugs: approach to overcome drug resistance to cisplatin. Onkol. 2009, N 1, 76–80. (In Russian).

      44. Sedova S. V., Avdeeva O. I., Balabanyan V. Yu., Makarov V. G., Makarova M. N., Hamdy Y. M., Shvets V. I. Сomparative experimental toxicological study of taxane cytostatics 1and their nanosized drug formulations. Rossiiskii bioterapevticheskii zh. 2013, N 4, 33–37. (In Russian).

      45. Shobolov D. L., Krasnopol'skij Ju. M., Ul'janov A. M., Natykan A. A., Tarasov V. V., Balaban'jan V. Ju., Shvec V. I., Prohorov V. V. Method for producing liposomal form of docetaxel. Eurasian patent No. 022182. November 30, 2015.

      46. Krasnopolsky Y. M., Dudnichenko А. S. Experimental study of liposomal docetaxel incorporation and stability. Exp. Oncol. 2017, 39 (2), 121–123. https://doi.org/10.31768/2312-8852.2017.39(2):121-123

      47. Monteiro N., Martins A., Reis R. L., Neves N. M. Liposomes in tissue engineering and regenerative medicine. J. R. Soc. Interface. 2014, 11 (101), 20140459. https://doi.org/10.1098/rsif.2014.0459

      48. Stepanov A. E., Krasnopolskiy Yu. M., Shvets V. I. Physiologically active lipids. Moskva: Nauka. 1991, 136 p. (In Russian).

      49. Shvets V. I. Phospholipids in biotechnology. Vestnik MITHT. 2009, 4 (4), 4–25. (In Russian).

      50. Hoogevest P., Wendel A. The use of natural and synthetic phospholipids as pharmaceutical exipients. Eur. J. Lipid Sci. Technol. 2014, 116 (9), 1088–1107. https://doi.org/10.1002/ejlt.201400219

      51. Krasnopolskij Ju. M., Grigoreva A. S., Kacaj A. G., Konahovich N. F., Prohorov V. V., Stadnichenko A. V., Balaban'jan V. Ju., Ljutik A. I., Shvetc V. I. Technologies and prospects for the use of liposomal drugs in clinical practice. Rossiyskie nanotehnologii. 2017, 12 (7–8), 132–141. (In Russian).

      52. Tuominen E. K., Wallace C. J., Kinnunen P. K. Phospholipid-cytochrome c interaction: evidence for the extended lipid anchorage. J. Biol. Chem. 2002, 277 (11), 8822‒8826. https://doi.org/10.1074/jbc.M200056200

      53. Pylypenko D., Katsai A., Prokhorov V., Konakhovich N., Grigoreva A., Krasnopolsky Yu. Investigation of antiarrhythmic activity of liposomal cytochrome C. Sci. J. ScienceRise: Pharm. Sci. 2017, 3 (7), 54–57. (In Russian). https://doi.org/10.15587/2519-4852.2017.104954

      54. Guan P., Wang P., Wang S. Cytochrome of ophthalmic drug delivery system. Azian J. Pharm. Sci. 2006, 1 (2), 118–125.

      55. Zhang J., Guan P., Wang T., Chang D., Jiang T., Wang S. Freeze-dried liposomes as potential carriers for ocular administration of cytochrome c against selenite cataract formation. J. Pharm. Pharmacol. 2009, 61 (9), 1171‒1178. https://doi.org/10.1211/jpp/61.09.0006

      56. Patel A., Cholkar K., Agrahari V., Mitra A. K. Ocular drug delivery systems: An overview. World J. Pharmacol. 2013, 2 (2), 47‒64. https://doi.org/10.5497/wjp.v2.i2.47

      57. Kumaraswamy S., Phanindra A., Nagaraj A., Anilgoud K., Shiva Kumar R. Liposomes as ocular drug delivery platforms: A review. Saudi J. Med. Pharm. Sci. 2017, 3 (7), 808–812. https://doi.org/10.21276/sjmps

      58. Honary Sh., Zahir T. Effect of zeta potencial on the properties of nano-drug delivery systems: a review (part 2). Tropical J. Pharm. Res. 2013, 12 (2), 265–273. https://doi.org/10.4314/tjpr.v12i2.20

      59. Kaiimoto K., Katsumi T., Nakamura T., Kataoka M., Harashima H. Liposome microcapsulation for the surface modification and improved entrapment of cytochrome c for targeted delivery. J. Am. Chem. Soc. 2018, 95 (1), 101–109. https://doi.org/10.1002/aocs.12026

      60. Pylypenko D., Prochorov V., Dudnichenko O., Krasnopolsky Y. Nanobiotechnological obtaininig of liposomal forms of antioхidant preparations based on bioflavonoide. Sci. J. ScienceRise: Pharm. Sci. 2019, 6 (22), 11–15. https://doi.org/10.15587/2519-4852.2019.188679

      61. Pylypenko D. M., Gorbach T. V., Krasnopolsky Y. M. The influence of complex liposomal antioxidant preparations on biological oxidative stress markers in ischemic heart disease. Biol. Markers Fundam. Clin. Med. (Sci. J.). 2020, V. 4, P. 18–19. https://doi.org/10.29256/v.04.01.2020.escbm05

      62. Kaddah S., Khreich N., Kaddah F., Charcosset C., Greige-Gerges H. Cholesterol modulates the liposome membrane fluidity and permeability for a hydrophilic molecule. Food Chem. Toxicol. 2018, V. 113, P. 40‒48. https://doi.org/10.1016/j.fct.2018.01.017

      63. Shakhmaiev A. E. Development of the technology for obtaining of the liposomal injectable form of ubidecarenone, having cardioprotective action. Ph.D thesis. Natsional technical university “Kharkiv polytechnic institute”, Ministry of Education and Science of Ukraine, Natsional University of Pharmacy, Ministry of Health of Ukraine, Kharkiv. 2017. (In Ukrainian).

      64. Pertsev I. M., Dmytriievskyi D. I., Rybachuk V. D. Excipients in drug technology. Kharkiv: Zoloti storinky. 2010, 598 p. (In Ukrainian).


 

Additional menu

Site search

Site navigation

Home Archive 2020 № 6 "QUALITY BY DESIGN" IN LIPOSOMAL DRUGS CREATION Yu. М. Krasnopolsky, D. М. Pylypenko

Invitation to cooperation

Dear colleagues, we invite you to publish your articles in our journal.
© Palladin Institute of Biochemistry of the National Academy of Sciences of Ukraine, 2008.
All rights are reserved. Complete or partial reprint of the journal is possible only with the written permission of the publisher.
E-mail
for information: biotech@biochem.kiev.ua.